Minutti-Palacios M

Idioma: Español
Referencias bibliográficas: 20
Paginas: 46-49
Archivo PDF: 822.77 Kb.

FRAGMENTO

CICLODEXTRINAS: QUÍMICA Y MECANISMO DE ACCIÓN

Las ciclodextrinas son oligosacáridos cíclicos obtenidos por degradación enzimática del almidón, formados por unidades de glucosa en configuración α-1,4 que conforman un tronco cónico truncado con interior hidrofóbico y exterior hidrofílico. Esta arquitectura les confiere capacidad de encapsulación molecular mediante la formación de complejos huésped-hospedero en proporción 1:1, sustentados en interacciones hidrofóbicas, fuerzas de van der Waals y puentes de hidrógeno —sin reacciones covalentes, pero termodinámicamente muy favorables.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kheterpal S, Vaughn MT, Dubovoy TZ, Shah NJ, Bash LD,Colquhoun DA, et al. Sugammadex versus neostigmine for reversal ofneuromuscular blockade and postoperative pulmonary complications(STRONGER): a multicenter matched cohort analysis. Anesthesiology. 2020;132:1371-1381.

2. Colquhoun DA, Vaughn MT, Bash LD, Janda A, Shah N, Ghafei A,et al. Association between choice of reversal agent for neuromuscularblock and postoperative pulmonary complications (STIL-STRONGER):a multicentre matched cohort study. Br J Anaesth. 2023;130:e148-e159.

3. Zhang Y, Jiang Y, Lei Q, Li C, Jin S, Wang Q, et al. Phase III clinical trialcomparing the efficacy and safety of adamgammadex with sugammadexfor reversal of rocuronium-induced neuromuscular block. Br J Anaesth.2024;132:45-52.

4. Zhao Y, Chen S, Xie W, Zhang X, Chen G, Ji F, et al. Efficacy andsafety of adamgammadex for reversing rocuronium-induced deepneuromuscular blockade: a multicenter, randomized, phase IIb study.Clin Transl Sci. 2024;17:e13691.

5. Zhao Y, Ren Y, Xie W, Wang Y, Lei Y, Zhu Y, et al. Efficacy andsafety of adamgammadex for reversing rocuronium-induced deepneuromuscular block: a multicentre, randomised, double-blind, positivecontrolledphase III trial. Br J Anaesth. 2025;135:331-339.

6. Hunter JM, Sneyd JR. Is adamgammadex the brother of sugammadexor the next generation of reversal agent? Br J Anaesth. 2024;132:15-17.

7. Qi YM, Qi YB, Yu BC, et al. Comparison of the efficacy and safety ofadamgammadex with sugammadex for reversal of rocuronium-inducedneuromuscular block: results of a phase II clinical trial. Drug Des DevelTher. 2022;16:4029-4036.

8. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safetyof sugammadex versus neostigmine in reversing neuromuscular blockadein adults. Cochrane Database Syst Rev. 2017;8:CD012763.

9. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned.Part I: Definitions, incidence, and adverse physiologic effects. AnesthAnalg. 2010;111:120-128.

10. Carron M, Veronese S, Foletto M, Ori C. Sugammadex allows fast-trackbariatric surgery. Obes Surg. 2013;23:1558-1563.

11. Badaoui R, Cabaret A, Alami Y, et al. Reversal of neuromuscularblockade by sugammadex in laparoscopic bariatric surgery: in supportof dose reduction. Anaesth Crit Care Pain Med. 2016;35:25-29.

12. Wong J, Farber A, Abreu M, et al. Impact of sugammadex versusneostigmine reversal on postoperative recovery time in patients withobstructive sleep apnea undergoing bariatric surgery. Anesth Analg.2025;140:568-576.

13. Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonarycomplications after use of muscle relaxants (POPULAR): a multicentre,prospective observational study. Lancet Respir Med. 2019;7:129-140.

14. Stauble CG, Blobner M. The future of neuromuscular blocking agents.Curr Opin Anaesthesiol. 2020;33:490-498.

15. Blobner M, Hunter JM, Meistelman C, et al. Use of a train-of-four ratioof 0.95 versus 0.9 for the reversal of rocuronium-induced neuromuscularblock: analysis of pooled data from four phase III clinical trials. Br JAnaesth. 2020;124:33-40.

16. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al.Calabadion: a new agent to reverse the effects of benzylisoquinolineand steroidal neuromuscular-blocking agents. Anesthesiology.2013;119:317-325.

17. Errando CL, Garutti I, Mazzinari G, et al. Residual neuromuscularblockade in the postanesthesia care unit: observational crosssectionalstudy of a multicenter cohort. Minerva Anestesiol.2016;82:1267-1277.

18. Leslie K, Chan MTV, Darvall JN, et al. Sugammadex, neostigmine andpostoperative pulmonary complications: an international randomisedfeasibility and pilot trial. Pilot Feasibility Stud. 2021;7:200.

19. Mulier JP, Dillemans B. Anaesthetic factors affecting outcomes afterbariatric surgery, a retrospective levelled regression analysis. Obes Surg. 2019;29:1841-1850.

20. Lott C, Truhlár A, Alfonzo A, et al. Actual versus ideal body weightdosing of sugammadex in morbidly obese patients. BMC Anesthesiol.2021;21:55.